SLS SELLAS Life Sciences Group Inc

$SLS SELLAS has historically operated on a bone-dry, ultra-frugal shoestring budget. They spent years keeping their head down, running a tiny 12-to-13 person staff, and watching every single penny to keep their clinical trials alive without burning through their limited cash. The contrast today is so stunning. Going from a company that watched every penny to suddenly hiring Simpson Healthcare (an elite, ultra-expensive global launch agency) and booking an expensive 20x30 mega-lounge at the main entrance of ASH right next to MD Anderson's Booth 2857 is a total behavioral breakdown. A historically thrifty company doesn't suddenly start spending like a Tier-1 pharmaceutical giant unless…

$SLS good morning to those of you who are up and checking the SLS board on a Saturday morning. What a great time to be a long bull. ❤️☀️ #40billy #godzilla

$SLS I used to think being diversified was smart and safe, but my portfolio didn’t make a lot of progress. Then I went all in on SLS. Glad I made the change,. I am anticipating an exciting 60 days or so, undiversified.

$SLS options activity is sending a remarkable signal with shares trading at $11.68. Call volume has reached 29.81K contracts versus only 6.79K puts, a ratio of approximately 4.4 to 1. The concentration is even more striking. The $15 strike recorded 10.7K calls against only 26 puts, while the $30 strike recorded another 10.39K calls against just 10 puts. Those two strikes alone account for 21.09K contracts, representing more than 70% of all call volume shown. Most contracts traded between the bid and ask, so the data cannot confirm that every call was purchased to open. Even so, this is extraordinary upside concentration. Whether driven by speculation, hedging, or strategic positioning, traders are showing overwhelming interest in call exposure far above the current share price. The options market is clearly preparing for the possibility of a significant move.

$SLS The OI in PUTS will be cut in half next Friday as 180k will expire worthless. Wonder if steviethebull still has his $5 P?

$SLS Look what Sellas Life's biggest clinical trial partner MD Anderson Cancer Cancer is exhibiting at ASH booth 2587 (size 20x20 with 4 presentations): "MD Anderson Cancer Center brings 4 presentations to ASH 2026 in New Orleans, and exhibits at Booth 2857. Its program is weighted toward acute myeloid leukemia and other myeloid cancers, from frontline treatment debates to targeted drugs and updated disease classification." Their booth size is 20x20 with 4 presentations. Sellas booth is bigger (20x30), and is the first one at the entrance to from the Poster hall to the Exhibition Hall. Everyone will pass Sellas Life FIRST on their left side when they enter the exhibition hall.

$SLS Ash conference booth space 600 square feet holds 60 to 75 people. How many work at SLS? 13. Looks like someone is planning a corporate meeting or cocktail party to celebrate............

$SLS visuals help people understand.. you don't need a 600 sq foot booth if you are there to present papers..or posters.. you can do it for free.. SEE..there is space to the LEFT..follow the Red arrow... BOOTHS have a different purpose.. ANCHORING BRAND PRESENCE.. for GPS and SLS009 platforms before the Sellas name is retired. Future owner demands this.. and that is why IQVIA is now involved.. Corporate basics.

$SLS I believe the fancy booth is about revealing a partnership and SLS009 PR. We’ll see, but it’s definately something to look for. Exciting times indeed!

$SLS Let’s look at the pipeline reality sls has two major assets. SLS-009 Phase 2b is on track to wrap up in Q4 (right before ASH), while GPS Event 80 might stretch into next year due to long-tail survival. So why would a tiny 13-person team suddenly drop big money on a massive 600 sq ft prime booth at ASH entrance something they never did A 600 sq ft buildout wouldn’t make sense if they were only betting on one uncertain trial timeline. Here is what is really happening This is a BP-directed playbook. BP is already deep in the background. Even if GPS Event 80 hasn’t fully crossed the finish line yet, interim and mature data show phenomenal trends, combined with the final SLS-009 dataset. The buyer didn’t just watch from the sidelines—they likely mandated this premier stage presence to prep for a full, multi-asset buyout. When a micro-cap breaks tradition and builds a fortress at the front of the hall, it’s because the deal structure is already being aligned behind the scenes.🚀🔥

$SLS ASH 2026 key dates: Event Dec 12-15th Abstract submissions (deadline August 4, 2026), registration openings in July–August 2026, and late-breaking abstracts in October 2026. You don’t set up a large booth to simply say “Hi we are in a quiet period but nice to meet you”! The countdown is on!

$SLS This is all about.. Joining the CLUB. ONE OF US.. the two platforms GPS and SLS009 live long.. Change of Control, while Sellas name gets retired. Welcome on Board!

$SLS science mean shit…it’s all about visibility. If MRNA owned GPS and SLS009 their stock would be $2000/share

$SLS Why would they hire Simpson Healthcare ahead of ASH Annual Meeting 😁 Ultimately, their role is to ensure that when a Phase 3 trial achieves positive data, the medical and scientific community fully understands, evaluates, and adopts the breakthrough therapy. Simpson Healthcare helps biotech and pharma companies achieve M&A readiness by translating complex scientific data into a compelling commercial narrative that demonstrates a drug's multi-billion dollar market value to potential Big Pharma buyers. I think a 600 Sq. Ft. Booth would be a great way to do this!

$SLS I know many from the bull camp are hoping for an 8-K simultaneously with top-line data and a COC contract, but personally, I am not for a pre-data M&A deal. 🤷‍♂️ If SELLAS follows the exact RVMD blueprint, they won't wait for a microphone slot at ASH. The second the data unblinds, they’ll just print the crushing survival win via a direct morning press release. I want to see the unblinded cards face up on the table first. This instantly forces an automated re-pricing floor on the open market, blowing up the short 🖕🏻 thesis overnight. As RVMD proved, dropping the numbers early establishes the asset's absolute truth valuation—forcing the Big Pharma suitors currently sitting in Stifel's data room under NDA to instantly stop lowballing and pay a true scarcity premium. Just my thoughts. NFA.

$SLS BP already know how a CDK9 inhibitor works and it is mostly about safety and 009 has already passed the safety test. RVMD is 6 times more effective with 009 for Pancreatic cancer. Who wants that type of cancer platform for 20 different cancers. All the big boys will jump in even at incomplete PH 2. Top Shelf!!! Top Dollar Drug!!!

$SLS Quick reminder , all 13F’s filed at this moment, are Q2 positions. Any 13F’s visible right now, are/were positions between April 1st and June 30th. For all we know, even before the 78th event announcement. (May 11th) Certainly before the extreme slow down in events, and certainly before the quiet period announcement. Q3 13F filings would be much more interesting , but we won’t know about them until the first 2 weeks of November

$SLS 😎🏖 SELLAS Life Sciences’ booth at ASH 2026 is reportedly 20 × 30 feet, equivalent to: * 600 square feet * Approximately 55.7 m² * Booth #138 — ASH 2026, New Orleans For comparison, MD Anderson Cancer Center’s booth is reportedly 20 × 20 feet, or approximately 37.2 m². If these dimensions are correct, SELLAS’ booth would be 50% larger. For a biotech company of SELLAS’ size that does not yet have an approved commercial drug, this would represent a substantial investment in visibility and presence at one of the world’s leading hematology conferences.

$SLS I couldn’t agree more. He certainly wouldn’t put a 600 square meter booth at the ASH conference. Great to read such logical thinking. You are right, they know it’s a complete lock 🔐

$SLS And btw, contrary to what some of the goofballs posted last week..IQVIA was NOT brought in to explain the Science to doctors in order to draw M&A interest.. They were brought in explicitly because large BP's use them to manage media, craft brand image, communicate patient stories and sales training. GPS and SLS009 platforms will be transferred to one or more of the large BPs. IQVIA provides continuity and brand support.